AKT2 and neoplasm: Although we did not examine concordance of results in the liquid versus the tissue biopsy cohort for alterations in genes other than PIK3CA, PTEN, AKT1, AKT2, and AKT3, our results support the value of blood-based NGS panel testing in providing a comprehensive tumor mutational landscape.